Eschweiler, Simon http://orcid.org/0000-0002-6379-8588
Ramírez-Suástegui, Ciro
Li, Yingcong http://orcid.org/0000-0002-0746-0531
King, Emma
Chudley, Lindsey
Thomas, Jaya
Wood, Oliver
von Witzleben, Adrian http://orcid.org/0000-0001-6766-4758
Jeffrey, Danielle http://orcid.org/0000-0003-3193-3420
McCann, Katy http://orcid.org/0000-0003-4388-7265
Simon, Hayley
Mondal, Monalisa
Wang, Alice
Dicker, Martina
Lopez-Guadamillas, Elena
Chou, Ting-Fang http://orcid.org/0000-0001-7095-3518
Dobbs, Nicola A.
Essame, Louisa
Acton, Gary
Kelly, Fiona
Halbert, Gavin
Sacco, Joseph J.
Schache, Andrew Graeme http://orcid.org/0000-0001-9466-6038
Shaw, Richard http://orcid.org/0000-0002-5157-4042
McCaul, James Anthony
Paterson, Claire
Davies, Joseph H.
Brennan, Peter A.
Singh, Rabindra P.
Loadman, Paul M. http://orcid.org/0000-0002-4259-8616
Wilson, William
Hackshaw, Allan http://orcid.org/0000-0002-5570-5070
Seumois, Gregory http://orcid.org/0000-0002-8164-6852
Okkenhaug, Klaus http://orcid.org/0000-0002-9432-4051
Thomas, Gareth J.
Jones, Terry M.
Ay, Ferhat http://orcid.org/0000-0002-0708-6914
Friberg, Greg
Kronenberg, Mitchell http://orcid.org/0000-0001-6318-6445
Vanhaesebroeck, Bart http://orcid.org/0000-0002-7074-3673
Vijayanand, Pandurangan http://orcid.org/0000-0001-7067-9723
Ottensmeier, Christian H. http://orcid.org/0000-0003-3619-1657
Article History
Received: 17 March 2021
Accepted: 24 March 2022
First Online: 4 May 2022
Competing interests
: G.F. is an employee of Amgen Inc. B.V. is a consultant for iOnctura (Geneva, Switzerland), Venthera (Palo Alto, US) and Olema Pharmaceuticals (San Francisco, US) and has received speaker fees from Gilead (Foster City, US). K.O. has received consultancy fees from iOnctura, Macomics, Gilead Sciences and Karus Therapeutics and has received research funding from GSK. M.K. is on the scientific advisory board of Prometheus. C.H.O. led the clinical trial of AMG319 with funding by Cancer Research UK, Amgen provided clinical grade compound free of charge for this trial. All other authors declare no conflicts of interest.